Parametric Portfolio Associates’s Aimmune Therapeutics AIMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-125,235
Closed -$4.31M 4071
2020
Q3
$4.31M Buy
125,235
+52,924
+73% +$1.13M ﹤0.01% 2005
2020
Q2
$1.21M Buy
72,311
+15,003
+26% +$255K ﹤0.01% 2813
2020
Q1
$826K Sell
57,308
-34,924
-38% -$893K ﹤0.01% 2902
2019
Q4
$3.09M Buy
92,232
+8,454
+10% +$236K ﹤0.01% 2399
2019
Q3
$1.75M Buy
83,778
+31,040
+59% +$634K ﹤0.01% 2716
2019
Q2
$1.1M Buy
52,738
+15,936
+43% +$328K ﹤0.01% 3005
2019
Q1
$823K Buy
36,802
+8,251
+29% +$194K ﹤0.01% 3127
2018
Q4
$683K Buy
28,551
+928
+3% +$24K ﹤0.01% 3168
2018
Q3
$754K Sell
27,623
-5,277
-16% -$149K ﹤0.01% 3242
2018
Q2
$885K Buy
32,900
+3,900
+13% +$119K ﹤0.01% 3113
2018
Q1
$923K Sell
29,000
-4,476
-13% -$158K ﹤0.01% 3064
2017
Q4
$1.27M Buy
33,476
+2,293
+7% +$74K ﹤0.01% 2892
2017
Q3
$773K Buy
31,183
+3,176
+11% +$68.5K ﹤0.01% 3178
2017
Q2
$576K Sell
28,007
-15,713
-36% -$300K ﹤0.01% 3280
2017
Q1
$950K Sell
43,720
-29,559
-40% -$606K ﹤0.01% 2888
2016
Q4
$1.5M Buy
73,279
+24,733
+51% +$506K ﹤0.01% 2577
2016
Q3
$728K Buy
48,546
+276
+0.6% +$3.73K ﹤0.01% 2981
2016
Q2
$522K Buy
48,270
+9,156
+23% +$124K ﹤0.01% 3166
2016
Q1
$530K Buy
39,114
+22,837
+140% +$356K ﹤0.01% 3298
2015
Q4
$300K Buy
+16,277
New +$301K ﹤0.01% 3565

Parametric Portfolio Associates's AIMT Position: Q4 2020 in Review

Parametric Portfolio Associates sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 125,235 shares — an estimated $4.31M sold.

Parametric Portfolio Associates first reported a position in AIMT in Q4 2015 and held it in 20 quarters. The position peaked at $4.31M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Parametric Portfolio Associates reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Parametric Portfolio Associates sold 125,235 Aimmune Therapeutics shares in Q4 2020, an estimated $4.31M.
  • Parametric Portfolio Associates first reported a position in Aimmune Therapeutics in Q4 2015 and held it in 20 quarters.
  • Parametric Portfolio Associates's Aimmune Therapeutics position peaked at $4.31M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Parametric Portfolio Associates's 13F filing for Q4 2020, filed 12 Feb 2021.